Capital Asset Advisory Services’s Spero Therapeutics SPRO Stock Holding History

Capital Asset Advisory Services’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.9K	Hold	32,548	–	–	﹤0.01%	370
2026 Q1	$92.4K	Hold	32,548	–	–	﹤0.01%	298
2025 Q4	$81.7K	Hold	32,548	–	–	﹤0.01%	289
2025 Q3	$61.2K	Hold	32,548	–	–	﹤0.01%	283
2025 Q2	$94.4K	Buy	+32,548	New	+$46.8K	﹤0.01%	269

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Asset Advisory Services's SPRO Position: Q2 2026 in Review

Capital Asset Advisory Services held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 32,548 shares worth $71.9K. The position accounts for ﹤0.01% of the portfolio, ranked #370.

Capital Asset Advisory Services first reported a position in SPRO in Q2 2025 and has held it in 5 quarters since. The position peaked at $94.4K in Q2 2025. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Capital Asset Advisory Services held 32,548 shares of Spero Therapeutics worth $71.9K as of Q2 2026.
Capital Asset Advisory Services left its Spero Therapeutics share count unchanged in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Capital Asset Advisory Services's portfolio in Q2 2026, its #370 holding.
Capital Asset Advisory Services first reported a position in Spero Therapeutics in Q2 2025 and has held it in 5 quarters since.
Capital Asset Advisory Services's Spero Therapeutics position peaked at $94.4K in Q2 2025.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Capital Asset Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.